If you have been reading about AOD-9604 and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2025-11-24. Where a claim depends on a specific study, the study is described rather than over-claimed.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
| Property | Value | Notes |
|---|---|---|
| Primary research area | Obesity and metabolic regulation | Studied in cell, animal, and human models |
| Highest reported trial phase | Phase II | Public summaries describe mixed results |
| Common route in trials | Subcutaneous injection | Typical for peptide therapeutics |
| Regulatory example | 2013 Australian anti-doping review | Classification was debated at the time |
| Approval status | Not approved as a human medicine | Status can change by jurisdiction |
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
Han Chinese also constitute the majority in both of the special administrative regions of the PRC. The Han Chinese in Hong Kong and Macau have been culturally, economically and politically dominant majority vis-à-vis the non-Han minorities.
Arthur 'Blaine' Bowman (born 1946 in Ogden, Utah, USA) is a leading proponent of ion chromatography, who has served variously as chairman, president, chief executive officer, and director of Dionex Corporation, a manufacturer of analytical instruments. Bowman received the 2015 Pittcon Heritage Award in recognition of his contributions to the field of ion chromatography. Arthur 'Blaine' Bowman was born in 1946 in Ogden, Utah, US. Around age 10, his family moved to Southern California, where he grew up. Bowman attended Brigham Young University in Provo, Utah in the physics program. As an undergraduate, he worked in the summer as an engineer at McDonnell Douglas, testing modules for the Apollo rocket. Bowman received his B.S. in physics in 1970. Next, Bowman worked as a product engineer at Motorola's Semiconductor Products Division in Phoenix, Arizona, where he became interested in business. He attended Stanford University's school of business from 1971 to 1973, receiving his M.B.A. in 1973. He then joined McKinsey & Company as a management consultant.
Naturally occurring niobium (41Nb) is composed of one stable isotope (93Nb). The most stable radioisotope is 92Nb with a half-life of 34.7 million years, followed by 94Nb at a half-life of 20,400 years and 91Nb at 680 years. Other radioisotopes that have been synthesized range from 82Nb to 110Nb; these have half-lives that are less than two hours, except 95Nb (34.991 days), 96Nb (23.35 hours) and 90Nb (14.60 hours). The most stable of the meta states is 93mNb with excitation energy 31 keV and a 16.1 year half-life; this is produced in the decay of 93Zr. The primary decay mode before stable 93Nb is electron capture to zirconium isotopes and the primary mode after is beta emission, with delayed neutron emission starting at 104Nb, leading to molybdenum isotopes. Only 95Nb, along with 97Nb (72 minutes) and heavier isotopes (seconds) are fission products in significant quantity, as the other isotopes are shadowed by stable or very long-lived (93) isotopes of the preceding element zirconium from the usual mode of production through beta decay of neutron-rich fission fragments. 95Nb is the decay product of 95Zr (64 days), so disappearance of 95Nb in used nuclear fuel is slower than would be expected from its own 35-day half-life alone.
Research on potential current public risk sources is published: the common DBP and BPAF appear to have "substantial impact on the integrity of the sperm nucleus and DNA structure" in mice via oxidative stress (5 May), a preliminary study contextualizes "time spent on social media" as one of the "least influential factors in adolescent mental health" (8 May), ubiquitous environmental contaminant TCE appears to be a risk factor for Parkinson's disease (PD) (15 May), various pesticides are identified as potential risk factors for PD (16 May), researchers demonstrate a two zero-day vulnerabilities-based quick low-cost method – "BrutePrint" – for bypassing common smartphones' fingerprint authentication (18 May), and common sucralose impurity sucralose-6-acetate appears to be DNA damaging with sucralose-sweetened drinks potentially far exceeding the threshold of toxicological concern (29 May). Promising innovations relating to global challenges are demonstrated: an open source automated experimentation science platform (BacterAI) for predicting microbial metabolism with little data (4 May), a pesticide alternative against wheat seed loss (22 May), a low-cost smartphone-attachment (BPClip) for blood pressure measurement (29 May), an open source transfer learning-based system (Geneformer) for predicting how networks of interconnected human genes control or affect the function of cells (31 May).
Sources: en.wikipedia.org
their intensive labouring demands and time consumption their confinements by the definition of the term defined by different standards. To solve this kind of difficulty, some regulatory bodies or methods provide advice on when performing of a specified system suitability test should be applied and compulsory.
=== Approaches === In keeping with the performance and mass range of available mass spectrometers, two approaches are used for characterizing proteins. In the first, intact proteins are ionized by either of the two techniques described above, and then introduced to a mass analyzer. This approach is referred to as "top-down" strategy of protein analysis as it involves starting with the whole mass and then pulling it apart. The top-down approach however is mostly limited to low-throughput single-protein studies due to issues involved in handling whole proteins, their heterogeneity and the complexity of their analyses. In the second approach, referred to as the "bottom-up" MS, proteins are enzymatically digested into smaller peptides using a protease such as trypsin. Subsequently, these peptides are introduced into the mass spectrometer and identified by peptide mass fingerprinting or tandem mass spectrometry. Hence, this approach uses identification at the peptide level to infer the existence of proteins pieced back together with de novo repeat detection. The smaller and more uniform fragments are easier to analyze than intact proteins and can be also determined with high accuracy, this "bottom-up" approach is therefore the preferred method of studies in proteomics. A further approach that is beginning to be useful is the intermediate "middle-down" approach in which proteolytic peptides larger than the typical tryptic peptides are analyzed.
== Medical use == A 2018 Cochrane review found that fluphenazine was an imperfect treatment and other inexpensive drugs less associated with side effects may be an equally effective choice for people with schizophrenia. Another 2018 Cochrane review found that there was limited evidence that newer atypical antipsychotics were more tolerable than fluphenazine. Intramuscular depot injection forms are available as both the decanoate and enanthate esters.
=== Menu options === The menus below are adapted from lists available on the website of the Defense Logistics Agency (DLA). UGR menus are regularly modified to improve their variety, nutrition, and efficiency. As the DLA does not regularly publish UGR menus. The lists below use the 2020 menu for the UGR-H&S, 2023 menu for the UGR-A, 2014 menu for the UGR-M, and 2021 menu for the UGR-E. Note that the lists below do not include milk, bread, fruit, or salad supplements, or items standard to most UGRs such as regular coffee and hot sauce.
==== Electrophoresis ==== Capillary electrophoresis (CE) and microcapillary gel electrophoresis (μCGE) are well-recognized microchip electrophoresis (MCE) methods that can provide numerous analytical advantages including high resolution, high sensitivity, and effective coupling to mass spectrometry (MS). Microchip electrophoresis can be applied generally as a method for high-throughput screening processes that help discover and evaluate drugs. Using MCE, specifically CE, microcapillary gel electrophoresis (μCGE) devices are created to perform high-number DNA sample processing, which makes it a good candidate for DNA analysis. μCGE devices are also practical for separation purposes because they use online separation, characterization, encapsulation, and selection of differing analytes originating from a composite sample. All of these advantages of MCE methods translate to microfluidic devices. The reason MCE methods are coupled to droplet-based microfluidic devices is because of the ability to analyze samples on the nanoliter scale. Using MCE methods on a small scale reduces cost and reagent use. Similarly to HPLC, fluorescence based detection techniques are used for capillary electrophoresis, which make these methods practical and can be applied to fields such as biotechnology, analytical chemistry, and drug development. These MCE and other electrophoresis based methods began to develop once capillary electrophoresis gained popularity in the 1980s and gained even more attention in the early 1990s, as it was reviewed nearly 80 times by the year 1992.
Sources: en.wikipedia.org
VOCs are also found in hospital and health care environments. In these settings, these chemicals are widely used for cleaning, disinfection, and hygiene of the different areas. Thus, health professionals such as nurses, doctors, sanitation staff, etc., may present with adverse health effects such as asthma; however, further evaluation is required to determine the exact levels and determinants that influence the exposure to these compounds. Concentration levels of individual VOCs such as halogenated and aromatic hydrocarbons vary substantially between areas of the same hospital. Generally, ethanol, isopropanol, ether, and acetone are the main compounds in the interior of the site. Following the same line, in a study conducted in the United States, it was established that nursing assistants are the most exposed to compounds such as ethanol, while medical equipment preparers are most exposed to 2-propanol. In relation to exposure to VOCs by cleaning and hygiene personnel, a study conducted in 4 hospitals in the United States established that sterilization and disinfection workers are linked to exposures to d-limonene and 2-propanol, while those responsible for cleaning with chlorine-containing products are more likely to have higher levels of exposure to α-pinene and chloroform.
Chemicals Hydroxylamine Base analogues (e.g., Bromodeoxyuridine (BrdU)) Alkylating agents (e.g., N-ethyl-N-nitrosourea (ENU). These agents can mutate both replicating and non-replicating DNA. In contrast, a base analogue can mutate the DNA only when the analogue is incorporated in replicating the DNA. Each of these classes of chemical mutagens has certain effects that then lead to transitions, transversions, or deletions. Agents that form DNA adducts (e.g., ochratoxin A) DNA intercalating agents (e.g., ethidium bromide) DNA crosslinkers Oxidative damage Nitrous acid converts amine groups on A and C to diazo groups, altering their hydrogen bonding patterns, which leads to incorrect base pairing during replication. Radiation Ultraviolet light (UV) (including non-ionizing radiation). Two nucleotide bases in DNA—cytosine and thymine—are most vulnerable to radiation that can change their properties. UV light can induce adjacent pyrimidine bases in a DNA strand to become covalently joined as a pyrimidine dimer. UV radiation, in particular longer-wave UVA, can also cause oxidative damage to DNA. Ionizing radiation. Exposure to ionizing radiation, such as gamma radiation, can result in mutation, possibly resulting in cancer or death. Whereas in former times mutations were assumed to occur by chance, or induced by mutagens, molecular mechanisms of mutation have been discovered in bacteria and across the tree of life. As S.
=== Quantification of proteins and biomolecules === There is an increasing trend of using ICP-MS as a tool in speciation analysis, which normally involves a front end chromatograph separation and an elemental selective detector, such as AAS and ICP-MS. For example, ICP-MS can be combined with size exclusion chromatography and preparative native PAGE for identifying and quantifying metalloproteins in biofluids. Also the phosphorylation status of proteins can be analyzed. In 2007, a new type of protein tagging reagents called metal-coded affinity tags (MeCAT) were introduced to label proteins quantitatively with metals, especially lanthanides. The MeCAT labelling allows relative and absolute quantification of all kind of proteins or other biomolecules like peptides. MeCAT comprises a site-specific biomolecule tagging group with at least a strong chelate group which binds metals. The MeCAT labelled proteins can be accurately quantified by ICP-MS down to low attomol amount of analyte which is at least 2–3 orders of magnitude more sensitive than other mass spectrometry based quantification methods. By introducing several MeCAT labels to a biomolecule and further optimization of LC-ICP-MS detection limits in the zeptomol range are within the realm of possibility. By using different lanthanides MeCAT multiplexing can be used for pharmacokinetics of proteins and peptides or the analysis of the differential expression of proteins (proteomics) e.g. in biological fluids.
Filament end-tracking protein (Formins, VASP and N-WASP) Filament-nucleator known as the Arp2/3 complex (Actin-related protein-2/3) Filament cross-linkers (e.g., α-actinin, fascin, and fimbrin) Actin monomer-binding proteins profilin and thymosin β4 Filament barbed-end cappers such as Capping Protein and CapG, etc. Filament-severing proteins like gelsolin. Actin depolymerizing proteins such as ADF/cofilin. The actin filament network in non-muscle cells is highly dynamic. The actin filament network is arranged with the barbed-end of each filament attached to the cell's peripheral membrane by means of clamped-filament elongation motors, the above-mentioned "actoclampins", formed from a filament barbed-end and a clamping protein (formins, VASP, Mena, WASP, and N-WASP). The primary substrate for these elongation motors is profilin-actin-ATP complex which is directly transferred to elongating filament ends. The pointed-end of each filament is oriented toward the cell's interior. In the case of lamellipodial growth, the Arp2/3 complex generates a branched network, and in filopodia a parallel array of filaments is formed.
Sources: en.wikipedia.org
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.
It became prominent during a 2013 Australian sports investigation that examined whether it was a prohibited growth-hormone-related substance. Subsequent interpretations and list updates have varied, so current rules should be checked directly.
Published summaries generally report limited or inconsistent weight-loss effects, and complete trial data are not widely available. The studies were not sufficient to establish it as an effective obesity treatment.
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.